Filtered By:
Cancer: Skin Cancer
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 2013 results found since Jan 2013.
Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma < em > via < /em > the PI3K/AKT pathway
CONCLUSION: Our study suggests for the first time that DDX51 promotes cancer cell proliferation by regulating the PI3K/AKT pathway; thus, DDX51 might be a therapeutic target for ESCC.PMID:35125830 | PMC:PMC8790558 | DOI:10.3748/wjg.v28.i4.464
Source: World Journal of Gastroenterology - February 7, 2022 Category: Gastroenterology Authors: Dong-Xin Hu Qi-Feng Sun Lin Xu Hong-Da Lu Fan Zhang Zhen-Miao Li Ming-Yan Zhang Source Type: research
Safety and Efficacy of TGF- β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
J Drugs Dermatol. 2022 May 1;21(5):472-477. doi: 10.36849/JDD.6384.ABSTRACTThis single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-β1/COX-2 combined with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing therapeutic in patients with cutaneous in situ squamous cell carcinoma. Twenty-five patients (mean age: 67, SD: 10 years; 52% men) with cutaneous in situ squamous cell carcinoma participated. TGF-β1/COX-2 siRNA/HKP nanoparticle therapeutic was injected weekly for up to 6 weeks based on the following do...
Source: Journal of Drugs in Dermatology - May 9, 2022 Category: Dermatology Authors: Mark Nestor Brian Berman Patrick Lu Michael Molyneaux Source Type: research
